Navigation Links
Drug Controller General to Withdraw Drug that Affects Vulture Population

Concerned at the effect of the anti-inflammatory drug Dicolofenec on the country's vulture population, the Drug Controller General has decided to withdraw licences for manufacturing it for veterinary use //.

At a press meet here today, the director of the prominent NGO Bombay Natural History Society (BNHS), Asad R Rahmani, presented a copy of Drug Controller General Ashwini Kumar's May 11 circular to all state drugs controllers to this effect.

The circular said with the approval of the Health Mministry, the licences granted for making Diclofenec for veterinary use should be withdrawn and the marketing of such formulations phased out within a period of three months.

Stating that serious concern had been expressed over the decline of the vulture population, the circular said extensive studies had indicated the use of Diclofenec among livestock was a major cause for this.

Expressing concern at the fall in the vulture population, Rahmani said his organisation had been urging the Centre to ban the drug for veterinary use.

Vultures are exposed to Diclofenec when they eat the carcasses of livestock treated with the drug before death, resulting in poisoning of the birds and their death because of kidney failure, the circular said.

It was, therefore, felt Diclofenec for veterinary use should be phased out and alternate safer and effective drugs like Meloxicam should be used for treating animals in veterinary healthcare.

This will help in saving the vulture population and the ecological balance in the animal world, Kumar said.


Page: 1

Related medicine news :

1. Bypass Heart Surgery Performed Without General Anesthesia
2. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
3. General Anesthesia For Heroin Detoxification Is No Good
4. General Practitioners are earning mighty amount?
5. Former IMO President Shows Interest In Winning General Election
6. Severe Paucity of General Practitioners in Australia
7. WHO Director-General passes away on 23rd of May
8. IT for General Practitioners
9. Fewer Graduates Choosing General Practice
10. Stroke Rehab Programs Should Be Generalized
11. China Nominates Margaret Chan to Run for WHO Director-Generals Post
Post Your Comments:

(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: